4D Molecular Therapeutics, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K events4D Molecular Therapeutics is a late-stage clinical biotech with no approved products, advancing the AAV gene therapy 4D-150 in Phase 3 for wet AMD and DME.
What they do
4DMT invents customized adeno-associated virus vectors using its Therapeutic Vector Evolution platform, which applies directed evolution in non-human primates to select tissue-targeted vectors. Its lead candidate, 4D-150, uses the R100 vector to deliver aflibercept and a VEGF-C RNAi payload via in-office intravitreal injection. Other programs include 4D-175 for geographic atrophy, 4D-710 for cystic fibrosis and 4D-725 for AATD. The company has no products approved for commercial sale and has not generated product revenue.
Revenue drivers
- Otsuka collaboration — An $85.0 million upfront payment under the October 2025 Otsuka agreement for 4D-150 rights in Japan, Korea, China, Australia and other Asia-Pacific markets; it drove the $85.1M revenue in Q4 2025. Up to $335.5 million in regulatory and commercial milestones plus tiered double-digit royalties are possible.
- Government or other collaboration revenue — Small residual amounts; 2024 revenue was only $37 thousand and Q1 and Q2 2026 revenue was $3.0 million and $3.8 million, respectively. These are not product sales.
- Future product sales — None today. 4D-150 would be the first commercial product if approved, with 4DMT retaining full U.S., Latin America and Europe rights outside the Otsuka territory.
Recent performance
Q2 2026 revenue was $3.8 million versus $85.1 million in Q4 2025, which included the Otsuka upfront. Cash, cash equivalents and marketable securities were $430.6 million at June 30, 2026, against total assets of $492.6 million and shareholder equity of $407.7 million. Full-year 2025 revenue was $85.2 million, and net loss was $140.1 million, or $2.42 diluted EPS. Operating cash use was $109.1 million in 2025 versus $134.6 million in 2024. Enrollment completed for 4FRONT-1 (N=523 randomized) and 4FRONT-2 (N>500 expected).
Strategy
The company's priority is advancing 4D-150 through Phase 3 in wet AMD and DME toward potential commercialization, while funding other programs such as 4D-175, 4D-710 and 4D-725 primarily through strategic alternatives. It secured a credit facility of up to $200 million from Hercules Capital, drawing $20 million initially, and reported cash runway into the second half of 2028. In DME, the FDA and EMA are aligned that a single Phase 3 trial may be acceptable for possible licensure. Otsuka leads regulatory and commercialization in Asia-Pacific, while 4DMT continues to lead global Phase 3 activity. An Investor Day is planned for October 21, 2026.
Risks
- No approved products or product revenue — The company has no products approved for commercial sale and has not generated product revenue, so future revenue depends entirely on clinical and regulatory success.
- Phase 3 readout risk — 4FRONT-1 topline is expected in Q2 2027 and 4FRONT-2 in H2 2027; failure or delay in either would materially affect the lead program.
- Cash burn and financing dependence — Operating cash use was $109.1 million in 2025, and the reported runway into the second half of 2028 depends on the Hercules facility and current operating plans.
- Pipeline prioritization — Further development of 4D-175 for geographic atrophy is pending financing, including potential strategic partnerships, so non-lead programs may be delayed.
Outlook
Management expects 4D-150 Phase 3 topline data from 4FRONT-1 in Q2 2027 and 4FRONT-2 in H2 2027, and plans to initiate a DME Phase 3 in Q3 2026. SPECTRA 2-year DME data and an AEROW Phase 1/2 update for 4D-710 are both expected in Q4 2026. The company states its cash position is expected to fund the current operating plan into the second half of 2028.